Methandrostenolon tablets (Tablets) Instructions for Use

Instructions
Dosage forms

ATC Code

A14AA03 (Metandienone)

Active Substance

Metandienone (Rec.INN registered by WHO)

Clinical-Pharmacological Group

Anabolic steroid drug

Pharmacotherapeutic Group

Anabolic steroid agent

Pharmacological Action

Anabolic steroid. Stimulates protein synthesis in the body, improves tissue trophism, promotes calcium deposition in bones.

Causes retention of nitrogen, phosphorus, sulfur, potassium, sodium, and water in the body.

Indications

Disorders of protein synthesis, cachexia of various origins. After injuries, burns, in pre- and postoperative periods, after radiation and infectious diseases.

In cases of renal and adrenal insufficiency, toxic goiter, muscular dystrophy, osteoporosis, as well as negative nitrogen balance associated with corticosteroid therapy, hypo- and aplastic anemias.

As part of complex therapy for tuberculosis, osteomyelitis, bronchial asthma, hepatitis.

ICD codes

Open the list of ICD codes

ICD-10 code	Indication
A15	Respiratory tuberculosis, bacteriologically and histologically confirmed
A17	Tuberculosis of nervous system
A18	Tuberculosis of other organs
B17.9	Acute viral hepatitis, unspecified
B18	Chronic viral hepatitis
D61.9	Aplastic anemia, unspecified
E05	Thyrotoxicosis [hyperthyroidism]
E27.4	Other and unspecified adrenocortical insufficiency
E46	Unspecified protein-energy malnutrition
G71.0	Muscular dystrophy
J45	Asthma
K73	Chronic hepatitis, not elsewhere classified
M80.9	Unspecified osteoporosis with pathological fracture
M81.9	Osteoporosis, unspecified
M86	Osteomyelitis
N18	Chronic kidney disease
R64	Cachexia
T14	Injuries to unspecified parts of body
T30	Burns and corrosions of unspecified body region
T66	Unspecified effects of radiation (radiation sickness)
Y42.0	Glucocorticoids and their synthetic analogues
Z54.0	Convalescence following surgery
Z54.1	Convalescence following radiotherapy
Z54.8	Convalescence following other treatment

ICD-11 code	Indication
1B10.0	Respiratory tuberculosis, bacteriologically or histologically confirmed
1B11.Z	Tuberculosis of nervous system, unspecified
1B12	Tuberculosis of other systems and organs
1E50.Z	Acute viral hepatitis, unspecified
1E51.Z	Chronic viral hepatitis, unspecified
2A60.40	Transient abnormal myelopoiesis
3A70.1Z	Acquired aplastic anemias, unspecified
5A02.Z	Thyrotoxicosis, unspecified
5A73	Hypoaldosteronism
5A74.Z	Adrenal insufficiency, unspecified
5A7Z	Adrenal gland diseases, unspecified
5B50	Deficiency of weight in infants, children and adolescents
5B51	Exhaustion in infants, children and adolescents
5B52	Acute protein-energy malnutrition in infants, children and adolescents
5B53	Growth delay in infants, children and adolescents
5B54	Underweight in adults
5B71	Protein deficiency
8C70.Z	Muscular dystrophy, unspecified
8E61.0	Radiation-induced brain injury
8E61.1	Radiation-induced spinal cord injury
CA23	Asthma
DB97.2	Chronic hepatitis, not elsewhere classified
FB83.1Z	Osteoporosis, unspecified
FB84.Z	Osteomyelitis or osteitis, unspecified
GB61.Z	Chronic kidney disease, unspecified stage
MG20.Z	Cachexia, unspecified
ND56.Z	Unspecified injury of unspecified part of trunk, limb or body region
NE11	Burn of unspecified body region
NF00	Exposure to radiation, not elsewhere classified
PL00	Drugs, medicaments or biological substances causing injury or harm in therapeutic use
QB7Y	Other specified convalescence
QB7Z	Convalescence, unspecified

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Administer tablets orally. For adults, initiate therapy at 10-20 mg per day, typically divided into multiple doses.

After achieving the desired therapeutic effect, transition to a maintenance dose of 5-10 mg per day.

For pediatric patients aged 5 to 14 years, the dose is 5 mg once daily.

Administer the daily dose to children either every day or on an every-other-day schedule as determined by the physician.

The total daily duration of treatment for any patient group should not exceed 4-6 weeks.

Following a treatment course, implement a mandatory therapy-free interval of 1-2 months.

For long-term therapy, closely monitor liver function tests and serum cholesterol levels.

Adjust dosage based on individual patient response and the severity of the condition being treated.

Adverse Reactions

Possible dyspeptic symptoms, transient jaundice, edema, voice coarsening, gynecomastia (predominantly in patients with liver cirrhosis).

In women – menstrual cycle disorders, virilization, increased libido, liver enlargement.

In children – premature ossification, virilization.

Contraindications

Prostate cancer, breast cancer in men, acute and chronic prostatitis. Pregnancy and lactation. Acute hepatic failure.

Use in Pregnancy and Lactation

Contraindicated for use during pregnancy and lactation.

Use in Hepatic Impairment

Contraindicated in acute hepatic failure.

Pediatric Use

For children and adolescents after a 4-week course, it is advisable to take a break of 1-2 months.

Special Precautions

For children and adolescents after a 4-week course, it is advisable to take a break of 1-2 months.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer